Johan Lund

Sa1095 THE HIGHLY SELECTIVE JAK1 INHIBITOR AQ280 COUNTERACTS INTERLEUKIN 13 AND ONCOSTATIN M-DRIVEN ESOPHAGEAL EPITHELIAL BARRIER DYSFUNCTION

Mirelle T. Kleuskens, Marie K. Bek, Anneli Tinnerholm, Wayne Russell et autres

Sa1095 THE HIGHLY SELECTIVE JAK1 INHIBITOR AQ280 COUNTERACTS INTERLEUKIN 13 AND ONCOSTATIN M-DRIVEN ESOPHAGEAL EPITHELIAL BARRIER DYSFUNCTION

Mirelle T. Kleuskens, Marie K. Bek, Anneli Tinnerholm, Wayne Russell et autres

Real-world outcomes in patients with relapsed and refractory multiple myeloma with prior proteasome inhibitor and lenalidomide exposure: A single-center study in Sweden

Vincent Luong, Muhammad Kashif, Katarina Uttervall, Anna Bohlin et autres

The use of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) such as lenalidomide (Len) in early lines of therapy in multiple myeloma (MM) has resulted in a high proportion of patients with relapsed or refractory multiple myeloma (RRMM) being Len-refractory. Len refractoriness …

se, fr, us (code pays fourni par la source)

Real-World Impact of Anti-CD38 Monoclonal Antibodies and Hematopoietic Stem Cell Transplant in Primary Plasma Cell Leukemia (2021 IMWG Criteria): A Single-Center Analysis

Vincent Luong, Katarina Uttervall, Monika Klimkowska, Hazel Reilly et autres

European Expert Panel Consensus on Outpatient Administration of Teclistamab and Talquetamab in Patients With Multiple Myeloma: Feasibility, Key Considerations, and Future Directions

Thomas Lund, Cyrus Khandanpour, Sébastien Anguille, Jens Kisro et autres

OBJECTIVES: Teclistamab and talquetamab treatments are typically initiated in a hospital due to the potential risk of cytokine release syndrome. However, emerging data support the potential for outpatient administration (i.e., administration without overnight hospital admission). An expert consensus survey and meeting were …

dk, de, be, at, se, nl, es, it, fr (code pays fourni par la source)

Mo1331: THE PLASMA PROTEOME IN EOSINOPHILIC ESOPHAGITIS REVEALS DISTINCT DISEASE ENDOTYPES AS WELL AS PREDICTORS OF TREATMENT RESPONSE TO TOPICAL STEROIDS: ANALYSIS OF SAMPLES FROM A RANDOMIZED CLINICAL TRIAL

Evan S. Dellon, Johan Lund, Wayne L. Russell, Jan Törnell et autres

Tu1741 PRECLINICAL DEVELOPMENT OF AQ312, A POTENT AND SELECTIVE SMALL MOLECULE ARYL HYDROCARBON AGONIST, FOR THE TREATMENT OF INFLAMMATORY BOWEL DISEASE.

Martin H. Johansson, Wayne L. Russell, Malin Hultqvist, Johan Lund

Su1280 CLINICAL DEVELOPMENT OF AQ280, A POTENT AND HIGHLY SELECTIVE JAK1 INHIBITOR, FOR THE TREATMENT OF EOSINOPHILIC ESOPHAGITIS

Anneli Tinnerholm, Martin H. Johansson, Malin Hultqvist, Fredrik Lindgren et autres

Identification of occupational risk factors by interviewing injured workers in an out-patient clinic

Johan Lund, Ebba Wergeland, Tone Lyse, Gunnar Tellnes

Background: To prevent injuries, identification of the involved risk factors is necessary. Two recent in-depth investigations were carried out in the health service of Oslo on workers seeking treatment of severe occupational injuries. The interviews were rather time-consuming, and hence rather costly. …

no (code pays fourni par la source)

A new Norwegian Injury Registration System as a starting point to assess the burden of injuries in Norway

Johan Lund

Abstract Introduction The police register is the main database for monitoring traffic injuries. A study made by Safe Traffic in Norway found that only one of three severe traffic injuries is registered in this register. For giving more complete data, a health-based …

Impact of newly diagnosed extramedullary myeloma on outcome after first autograft followed by maintenance: A CMWP‐EBMT study

Nico Gagelmann, Dirk‐Jan Eikema, Linda Köster, Tanja Netelenbos et autres

BACKGROUND: No adequate data exist on the impact of multiple myeloma (MM) with extramedullary disease (EMD) after autograft and maintenance therapy. METHODS: We identified 808 patients with newly diagnosed MM who received first autograft, of whom 107 had EMD (83 paraskeletal and …

de, nl, Afrique du Sud, fr, gr, it, hu, fi, tr, Algérie, se, ie (code pays fourni par la source)

Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide

Maria Karvouni, Marcos Vidal-Manrique, Katharina H. Susek, Alamdar Hussain et autres

Background aims Adoptive cell therapy with chimeric antigen receptor (CAR)-expressing natural killer (NK) cells is an emerging approach that holds promise in multiple myeloma (MM). However, the generation of CAR-NK cells targeting CD38 is met with obstacles due to the expression of …

se, us (code pays fourni par la source)